A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
Active, not recruiting · NCT06211634 · Registry updated 2026-09-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Glanzmann thrombasthenia 1, Hemic and Lymphatic Diseases, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-25 | NCT06211634 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hemab ApS | 6 |
17 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.